QGEN — QIAGEN N.V.

—
NYSE · Health Care · Biotechnology · CIK 1015820 · Netherlands
Last close
$44.18
Market Cap
$9.12B
52W High
$57.30
52W Low
$32.24
ADV30
2,417,737
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 535,040,000 340,386,000 140,850,000 103,401,000 5,889,202,000 768,500,000 2,531,462,000
Mar 2026 492,320,000 309,603,000 116,626,000 68,043,000 5,782,065,000 646,289,000 2,450,359,000
Dec 2025 540,420,000 325,269,000 121,880,000 107,829,000 6,281,232,000 839,005,000 2,503,078,000
Sep 2025 532,583,000 331,259,000 137,293,000 130,043,000 6,553,497,000 1,355,594,000 2,904,082,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$615,215,000
Investing CF
$-213,886,000
Financing CF
$-395,931,000
CapEx
$-211,343,000
Dividends Paid
$1,000
Buybacks
$0
EPS Diluted TTM
$1.94
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$2,802,017,000
Inventory
$309,606,000
Receivables
$396,616,000
ST Investments
$0
EBIT TTM
$493,558,000
Pretax Income TTM
$456,545,000
Interest Exp TTM
$37,013,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,100,363,008
EBITDA
$734,185,024
Free Cash Flow
$372,855,136
Enterprise Value
$9,636,236,288
Total Cash
$793,500,032
Total Debt
$1,653,698,944
Shares Out
206,495,000
Trailing EPS
$1.97
Book Value
$16.26
ROE
11.9%
ROA
5.9%
Div Yield
0.83%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,089,999,000 520,310,000 424,880,000 6,281,232,000 2,503,078,000 3,778,154,000 654,326,000
Dec 2024 1,978,214,000 199,899,000 83,591,000 5,689,622,000 2,122,283,000 3,567,339,000 673,551,000
Dec 2023 1,965,311,000 445,247,000 341,303,000 6,115,190,000 2,307,426,000 3,807,764,000 459,455,000
Dec 2022 2,141,518,000 576,228,000 423,211,000 6,287,735,000 2,821,124,000 3,466,611,000 715,264,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.61

Max Pain — expiry 2026-10-16

max pain strike: $45.00 · spot: $44.94 · call oi: 4,559 · put oi: 3,011
Expected Move to 2026-10-16: ±$3.10 (6.90%) — implied range $41.84 – $48.04 · ATM straddle on $45.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
KYMR Kymera Therapeutics, Inc. $9.21B $111.95 —
IBRX ImmunityBio, Inc. $8.95B $8.44 —
PCVX Vaxcyte, Inc. $8.36B $56.21 —
KRYS Krystal Biotech, Inc. $10.24B $345.82 —
RGEN REPLIGEN CORP $10.70B $189.68 —

News headlines (Yahoo Finance, 1h cache)

Magnetic Beads - Global Strategic Business Report: Capitalize on the Surge from $3.3 Billion in 2025 to $7.4 Billion by 2032 as Thermo Fisher Scientific, Merck KGaA, QIAGEN, Bio-Rad Laboratories and M
2026-09-28 08:07 · Yahoo
QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation
2026-09-24 20:05 · Yahoo
QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board
2026-09-18 20:05 · Yahoo
Genomics Market Outlook 2026-2035 - Featuring Profiles of Illumina, Thermo Fisher Scientific, and Qiagen
2026-09-18 10:44 · Yahoo
Pharmacogenomics Market Outlook 2026-2035 - Featuring Profiles of Thermo Fisher Scientific, Illumina, and Qiagen
2026-09-18 10:43 · Yahoo
Qiagen Shares Rise 4% Following Report of Private Equity Takeover Interest
2026-09-17 12:32 · Yahoo
QIAGEN (QGEN) Rolls Out QIAsymphony Connect Following Q2 Outperformance
2026-09-17 05:20 · Yahoo
Transcriptome Sequencing Market - Global Forecast to 2035; Bulk RNA-Seq Maintains Its Technology Market Lead
2026-09-10 11:03 · Yahoo
Qiagen (QGEN) Beat Q2 Estimates And Reaffirmed Outlook, Is It Still Below Fair Value?
2026-09-05 21:06 · Yahoo
Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue?
2026-09-04 15:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.